ライフサイエンスコーパス: B-type natriuretic peptide

1 /=290 pg/mL) serum NT-proBNP (N-terminal pro-B-type natriuretic peptide).

2 nd, and biomarkers (including N-terminal pro-B-type natriuretic peptide).

3 troponin T) and dysfunction (N-terminal pro-B-type natriuretic peptide).

4 e, hematocrit, and NT-proBNP (N-terminal pro b-type natriuretic peptide).

5 ricular ejection fraction and N-terminal pro-B-type natriuretic peptide.

6 ore, left ventricular ejection fraction, and B-type natriuretic peptide.

7 en for C-reactive protein and N-terminal pro B-type natriuretic peptide.

8 ed preoperative end-systolic volume index or B-type natriuretic peptide.

9 ted by further adjustment for N-terminal pro-B-type natriuretic peptide.

10 r matrix turnover), ST-2, and N-terminal pro-B-type natriuretic peptide.

11 endothelin-1, creatinine, and N-terminal pro-B-type natriuretic peptide.

12 r elevated baseline levels of N-terminal pro B-type natriuretic peptide.

13 imer, cardiac troponin T, and N-terminal pro-B-type natriuretic peptide.

14 measurement of the ventricular stress marker B-type natriuretic peptide.

15 tration, and 0.76 (0.60-0.93) for changes in B-type natriuretic peptide.

16 other risk factors including N-terminal pro-B-type natriuretic peptide.

17 lated with the cardiac marker N-terminal pro-B-type natriuretic peptide.

18 rognostic variables including N-terminal pro-B-type natriuretic peptide.

19 markers (including NT-proBNP [N-terminal pro-B-type natriuretic peptide]).

20 f troponin T (0.05 ng/ml) and N-terminal pro-B-type natriuretic peptide (3,000 pg/ml).

21 ection fraction (ejection fraction=63+/-15%; B-type natriuretic peptide=431+/-366 pg/mL) was conducte

22 Secondary endpoints were quality of life, B-type natriuretic peptide, 6-min walk distance, and EF.

23 124 (69-197) ng/L, NT-proBNP (N-terminal-pro-B-type natriuretic peptide) 624 (307-1312) ng/L, hs-cTnI

24 troponin (83.0 vs. 28.5 ng/L; P < 0.05), and B-type natriuretic peptide (7,424.5 vs. 3,209.5 pg/mL; P

25 Plasma aldosterone, B-type natriuretic peptide, active renin concentration,

26 molecular markers, including Nppb, encoding B-type natriuretic peptide, after infarction.

27 Patients with AF had higher N-terminal pro-B-type natriuretic peptide, aldosterone, endothelin-1, t

28 ted lipocalin) and NT-proBNP (N-terminal pro-B-type natriuretic peptide; all P<0.001).

29 NT-proBNP (N-terminal pro-B-type natriuretic peptide) alone at a cutoff of >800 id

30 concentration, hemoglobin concentration, and B-type natriuretic peptide also significantly increased

31 lded modest improvement over a model without B-type natriuretic peptide and ankle-brachial index (C s

32 Patients had echocardiograms and measures of B-type natriuretic peptide and C-reactive protein before

33 Preoperative N-terminal pro-B-type natriuretic peptide and cardiovascular events aft

34 ial infarction (AMI) by using N-terminal pro-B-type natriuretic peptide and Global Registry of Acute

35 Circulating N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac

36 Plasma concentrations of N- terminal pro-B-type natriuretic peptide and high-sensitivity cardiac

37 ncludes age, biomarkers (N-terminal fragment B-type natriuretic peptide and high-sensitivity cardiac

38 tional impairment, and higher N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin

39 estimate the values of serum N-terminal pro-B-type natriuretic peptide and procalcitonin and the cha

40 ence of heterogeneity between N-terminal pro B-type natriuretic peptide and saxagliptin (P for intera

41 blished biomarkers of post-MI HF: N-terminal B-type natriuretic peptide and troponin T, and newly eme

42 rdial wall stress and injury (N-terminal pro-B-type natriuretic peptide and troponin) versus enalapri

43 use of natriuretic peptides (N-terminal pro-B type natriuretic peptide) and rest/exercise echocardio

44 omes were (1) mean NT-proBNP (N-terminal pro b-type natriuretic peptide) and (2) proportion of patien

45 levels of cardiac biomarkers (troponins and B-type natriuretic peptide) and cardiac dysfunction for

46 PASP and potential mediators, including BNP (B-type natriuretic peptide) and endothelin-1.

47 In contrast to NT-proBNP (N-terminal pro-B-type natriuretic peptide) and hs-TnT (high-sensitivity

48 -terminal pro-atrial natriuretic peptide and B-type natriuretic peptide) and lower blood concentratio

49 Both BNP (B-type natriuretic peptide) and NT-proBNP (N-terminal pr

50 change in primary (change in N-terminal pro B-type natriuretic peptide) and secondary (change in lef

51 eft atrial volume, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and fibrosis biomarkers; an

52 ty troponin T (hsTnT), NT-proBNP (N-terminal B-type natriuretic peptide), and growth differentiation

53 ed concentrations of glucose, N-terminal pro-B type natriuretic peptide, and cystatin C.

54 le combination of standard CVD risk factors, B-type natriuretic peptide, and ankle-brachial index (mo

55 Operative Risk Evaluation II, N-terminal pro-B-type natriuretic peptide, and cardiac troponin T conce

56 sed plasma norepinephrine and N-terminal pro-B-type natriuretic peptide, and chemosensitivity to hype

57 line body mass index, height, N-terminal pro-B-type natriuretic peptide, and cystatin C, with longer

58 based on cardiac troponin I, N-terminal pro-B-type natriuretic peptide, and d-dimer levels at baseli

59 Cardiac troponin I, N-terminal pro-B-type natriuretic peptide, and d-dimer levels were meas

60 high-sensitivity troponin T, N-terminal pro-B-type natriuretic peptide, and high-sensitivity C-react

61 or conventional risk markers, N-terminal pro-B-type natriuretic peptide, and hs-TnT, hs-TnI levels in

62 ficantly greater reduction in N-terminal pro-B-type natriuretic peptide, and improved clinical outcom

63 rular filtration rate, higher N-terminal pro-B-type natriuretic peptide, and ischemic cause of heart

64 of angiotensin inhibition therapy, elevated B-type natriuretic peptide, and larger left ventricular

65 n, d-dimer, homoarginine, and N-terminal pro B-type natriuretic peptide, and lower levels of low-dens

66 rular filtration rate, higher N-terminal pro-B-type natriuretic peptide, and lower peak Vo(2).

67 , glomerular filtration rate, N-terminal pro-B-type natriuretic peptide, and peak oxygen consumption

68 ctional class or Ross class), N-terminal pro-B-type natriuretic peptide, and quality of life (QOL) we

69 cle ergometry, measurement of N-terminal pro-B-type natriuretic peptide, and subjective health assess

70 tive protein, lipoprotein(a), N-terminal pro-B-type natriuretic peptide, and transferrin), and apolip

71 action, pericardial effusion, N-terminal pro-B-type natriuretic peptide, and troponin T.

72 sensitivity troponin and N-terminal fragment B-type natriuretic peptide], and clinical history of pri

73 cardiac troponins, NT-proBNP [N-terminal pro-B-type natriuretic peptide], and galectin-3).

74 oncentrations, hemoglobin concentration, and B-type natriuretic peptide are reliable alternatives to

75 retic peptide) and NT-proBNP (N-terminal pro B-type natriuretic peptide) are widely used to aid diagn

76 tic resonance imaging and BNP/N-terminal pro-B-type natriuretic peptide, are emerging as promising in

77 rasound (28-scanning point method), and BNP (B-type natriuretic peptide) assessment during supine exe

78 rement of soluble ST2 and amino-terminal pro-B-type natriuretic peptide at 12 hours added value to Ca

79 We measured B-type natriuretic peptide at hospital admission in acut

80 ive troponin-T and NT-proBNP [N-terminal Pro-B-type natriuretic peptide]) at baseline (pre-ERT) and 1

81 and are associated with HF more closely than B-type natriuretic peptide (AUC = 0.97 versus 0.84, p =

82 N-terminal pro B-type natriuretic peptide (available in 2632 patients)

83 natriuretic peptides, such as N-terminal pro-B-type natriuretic peptide/B-type natriuretic peptide, t

84 cted to define the association between serum B-type natriuretic peptide (BNP) activation and survival

85 rial, we determined whether plasma levels of B-type natriuretic peptide (BNP) and cardiac troponin I

86 las Heart Study underwent measurements of 1) B-type natriuretic peptide (BNP) and N-terminal pro-B-ty

87 dy was to determine the relationship between B-type natriuretic peptide (BNP) and survival in patient

88 peptide (NP) family, which also includes the B-type natriuretic peptide (BNP) and the C-type natriure

89 Measurement of B-type natriuretic peptide (BNP) and the cardiological e

90 designed to monitor daily concentrations of B-type natriuretic peptide (BNP) and to determine how th

91 ata on the prognostic value of postoperative B-type natriuretic peptide (BNP) are scarce.

92 Cardiac troponin and B-type natriuretic peptide (BNP) concentrations are asso

93 h-sensitivity C-reactive protein (hsCRP) and B-type natriuretic peptide (BNP) concentrations at 72 h

94 With sacubitril/valsartan treatment, B-type natriuretic peptide (BNP) concentrations increase

95 eptides are substrates of neprilysin; hence, B-type natriuretic peptide (BNP) concentrations rise wit

96 eptides atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) in heart tissue may als

97 secrete atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) in response to mechanic

98 B-type natriuretic peptide (BNP) is a guanylyl cyclase A

99 Numerous experimental studies suggest that B-type natriuretic peptide (BNP) is cardioprotective; ho

100 correlation between TMAO concentrations and B-type natriuretic peptide (BNP) levels (r = 0.23; p < 0

101 Studies suggesting that B-type natriuretic peptide (BNP) may predict outcomes of

102 Serum B-type natriuretic peptide (BNP) plays an important role

103 nators in serum by LR were troponin I (TnI), B-type natriuretic peptide (BNP), and creatine kinase-MB

104 lated with an established biomarker for CVD, B-type Natriuretic Peptide (BNP), and echocardiographic

105 ardiograph, a decreasing or normalization of B-type natriuretic peptide (BNP), and hemodynamics with

106 Circulating RBP4, TTR, B-type natriuretic peptide (BNP), and troponin I (TnI) c

107 (NPs), atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), have central roles in

108 The utility of B-type Natriuretic Peptide (BNP), N-terminal proBNP (NT-

109 trial natriuretic peptide (ANP) and brain or B-type natriuretic peptide (BNP), thereby demonstrating

110 We have reported that pro-B-type natriuretic peptide (BNP)-1-108 circulates and is

111 uding left ventricular ejection fraction and b-type natriuretic peptide (BNP).

112 ine C34:4, has a diagnostic value similar to B-type natriuretic peptide (BNP).

113 , were divided into a labeled data set (with B-type natriuretic peptide [BNP] result as a marker of C

114 L/m(2) (P=0.0042) and reduced N-terminal pro-B-type natriuretic peptide by 28% (2%-47%), P=0.038.

115 ion, the levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) by 36% (32 800 +/- 24 300 ng

116 for mortality in addition to N-terminal pro-B-type natriuretic peptide (C-statistic: 0.59 versus 0.6

117 in T, creatine kinase, myoglobin, N-terminal B-type natriuretic peptide, C-reactive protein, and leuk

118 tudinal changes in NT-proBNP (N-terminal pro-B-type natriuretic peptide), cardiac reverse remodeling,

119 n, lower expression of cardiac stress genes (B-type natriuretic peptide, collagen gene expression), l

120 (48 versus 40), higher median N-terminal pro-B-type natriuretic peptide concentration (403 versus 320

121 in extracellular fluid volume, and in plasma B-type natriuretic peptide concentration (ratio of inter

122 (-5.1 to -0.8, p=0.0070), and N-terminal pro B-type natriuretic peptide concentration in plasma -970

123 as associated with NT-proBNP (N-terminal pro-B-type natriuretic peptide) concentration (0.57 on a log

124 the kallikrein B locus were associated with B-type natriuretic peptide concentrations in blacks.

125 After extensive adjustments, N-terminal pro-B-type natriuretic peptide concentrations predicted ICU

126 N-terminal pro-B-type natriuretic peptide declined significantly in all

127 cretoneurin measurements, and N-terminal pro-B-type natriuretic peptide did not improve patient class

128 ty of disease as indicated by N-terminal pro B-type natriuretic peptide, E/E', and left atrial volume

129 ent after adjustment for age, N-terminal pro-B-type natriuretic peptide, ejection fraction, E/E', and

130 e from baseline to week 12 in N-terminal pro-B-type natriuretic peptide, ejection fraction, global lo

131 ANP (atrial natriuretic peptide) and BNP (B-type natriuretic peptide), encoded by the clustered ge

132 hared HF proteins (NT-proBNP [N-terminal pro-B type natriuretic peptide], ESM [endothelial cell-speci

133 ignificantly raised levels of N-terminal pro B-type natriuretic peptide, ferritin, D-dimers, and card

134 6.2% to 27.1+/-6.6%; P=0.23), N-terminal pro B-type natriuretic peptide (from 3322+/-3411 to 3672+/-5

135 ; P=0.001), and a decrease in N-terminal pro B-type natriuretic peptide (from 3672+/-5165 to 1488+/-1

136 Exercise testing, echocardiography, B-type natriuretic peptide, functional health assessment

137 high-sensitivity troponin T, N-terminal pro-B-type natriuretic peptide, growth-differentiation facto

138 elevated cardiac biomarkers (N-terminal pro-B-type natriuretic peptide [>40 pg/mL] or troponin T [>0

139 DS(2) score >2, or NT-proBNP (N-terminal pro-B-type natriuretic peptide) >=40 pmol/L and among partic

140 le ST2, >/= 500 ng/mL and amino-terminal pro-B-type natriuretic peptide, >/= 4,500 ng/L) had higher 3

141 Assessment of BNP (B-type natriuretic peptide) has also been suggested by t

142 traditional risk factors and N-terminal pro-B-type natriuretic peptide (hazard ratio per SD incremen

143 n time, left atrium dimension, E/e', and pro B-type natriuretic peptide (hazard ratio, 1.05; 95% conf

144 0.84 to 0.99; p = 0.027) and N-terminal pro-B-type natriuretic peptide (hazard ratio: 0.98; 95% conf

145 CI, 1.1-1.39]) and NT-proBNP (N-terminal pro-B-type natriuretic peptide; hazard ratio, 1.73 [95% CI,

146 reactive protein), NT-proBNP (N-terminal pro-B-type natriuretic peptide), HbA1C (glycated hemoglobin)

147 on functional class [WHO-FC], N-terminal-pro-B-type natriuretic peptide, hemodynamics) and lung-trans

148 ECG, coronary artery calcium, N-terminal pro B-type natriuretic peptide, high-sensitivity cardiac tro

149 ECG, coronary artery calcium, N-terminal pro B-type natriuretic peptide, high-sensitivity cardiac tro

150 Levels of N-terminal fragment B-type natriuretic peptide, high-sensitivity cardiac tro

151 sponse to LCZ696 for lowering N-terminal pro B-type natriuretic peptide; however, left atrial volume

152 We also assayed NT-proBNP (N-terminal pro-B-type natriuretic peptide), hs-cTnT, CRP (C-reactive pr

153 Plasma levels of B-type natriuretic peptide, hs-TnI (high-sensitivity tro

154 elevation in inflammatory markers, D-dimer, B-type natriuretic peptide, IL-6, and IL-10 levels were

155 luding clinical variables and N-terminal pro-B-type natriuretic peptide) improved discrimination (C-s

156 ssment (11 risk factors) plus N-terminal pro-B-type natriuretic peptide in terms of discrimination, c

157 When including B-type natriuretic peptide in the model, only a decreasi

158 11% vs. 55 +/- 10%; p < 0.001; n = 259), and B-type natriuretic peptide increased (median [interquart

159 eight loss, reduction in amino terminal, pro B-type natriuretic peptide, increased plasma renin activ

160 res of cystatin C, NT-proBNP (N-terminal pro-B-type natriuretic peptide), interleukin (IL)-6, and E-s

161 erum ferritin, procalcitonin, N-terminal pro B-type natriuretic peptide, interleukin-6 level, and D-d

162 , matrix metalloproteinase-3, N-terminal pro-B-type natriuretic peptide, interleukin-6, soluble CD40

163 , matrix metalloproteinase-3, N-terminal pro-B-type natriuretic peptide, interleukin-6, soluble CD40

164 after myocardial infarction, indicating that B-type natriuretic peptide is required to preserve posti

165 Background NT-proBNP (N-terminal pro-B-type natriuretic peptide) is useful in diagnosis and p

166 eraged proportional change in N-terminal pro-B-type natriuretic peptide level from baseline to 180 da

167 se (CVD), a 10-year risk of CVD < 20%, and a B-type natriuretic peptide level greater than their gend

168 of 25% [IQR, 19%-33%]; median N-terminal pro-B-type natriuretic peptide level of 2049 pg/mL [IQR, 105

169 variable HR for a 1-SD higher N-terminal pro-B-type natriuretic peptide level, 1.15; 95% CI, 1.04-1.2

170 level, troponin T level, log N-terminal pro-B-type natriuretic peptide level, fibroblast growth fact

171 water indexed for ideal body weight, plasma B-type natriuretic peptide level, hemoglobin, and plasma

172 Age, B-type natriuretic peptide level, renal dysfunction, 24-

173 al therapy but fewer comorbidities and lower B-type natriuretic peptide level.

174 N-Terminal pro-B type natriuretic peptide levels were below the level c

175 CI, 1.55-2.44), and abnormal N-terminal pro-B-type natriuretic peptide levels (defined as >400 pg/mL

176 currence rates in addition to an increase in B-type natriuretic peptide levels (P=0.01), C-reactive p

177 Serum N-terminal pro-B-type natriuretic peptide levels and certain hemodynami

178 N-terminal pro-B-type natriuretic peptide levels decreased similarly in

179 B-type natriuretic peptide levels increased over time an

180 hospitalized with acute coronary syndromes, B-type natriuretic peptide levels measured at admission

181 ad NT-proBNP levels of 1000 pg/mL or more or B-type natriuretic peptide levels of 250 pg/mL or more,

182 both), in contrast to plasma N-terminal pro-B-type natriuretic peptide levels that were not (area un

183 N-terminal pro-B-type natriuretic peptide levels were abnormal in 97.4%

184 B-type natriuretic peptide levels were higher in acute k

185 B-type natriuretic peptide levels were measured at rest

186 In contrast, N-terminal pro-B-type natriuretic peptide levels were not associated wi

187 worse quality of life, higher N-terminal pro-B-type natriuretic peptide levels, and a poorer prognosi

188 ntricular function, decreased N-terminal pro B-type natriuretic peptide levels, and better exercise c

189 minute walk distances, higher N-terminal pro-B-type natriuretic peptide levels, and the presence of r

190 In Cox Proportional Hazard analyses, B-type natriuretic peptide levels, C-reactive protein le

191 mL]; P<0.0001), despite lower N-terminal pro-B-type natriuretic peptide levels.

192 ventricular ejection fraction, or N-terminal B-type natriuretic peptide levels.

193 umin had significantly higher N-terminal pro-B-type natriuretic peptide levels; in addition, early ri

194 interleukin-6) and NT-proBNP (N terminal pro B-type natriuretic peptide) levels were examined in mult

195 uble receptors and NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) levels were important across

196 ejection fraction, NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels, cardiac output/index

197 Although LCZ696 reduced N-terminal pro B-type natriuretic peptide, levels of the other 4 biomar

198 ss, mitral regurgitation, and N-terminal pro-B-type natriuretic peptide, lower TAPSE, and assignment

199 nin-T) <6 ng/L and NT-proBNP (N-terminal pro-B-type natriuretic peptide) <100 pg/mL), and those with

200 N-terminal pro-B-type natriuretic peptide (median: 11.6 pmol/l [interqu

201 d glomerular filtration rate, N-terminal pro-B-type natriuretic peptide, mineralocorticoid receptor a

202 s strong as that obtained for N-terminal pro-B-type natriuretic peptide (multivariable HR for a 1-SD

203 oplasmin, nitrotyrosine-bound ceruloplasmin, B-type natriuretic peptide, norepinephrine, and high-sen

204 Ceruloplasmin, B-type natriuretic peptide, norepinephrine, and high-sen

205 ad normalised, and who had an N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) concentration le

206 on fraction (LVEF) >=55%, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) >=300 pg/ml.

207 N-terminal pro-B-type natriuretic peptide (NT-proBNP) and circumferenti

208 was drawn for the biomarkers N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitiv

209 Serum N-terminal-pro-B-type natriuretic peptide (NT-proBNP) and total testost

210 rdiac troponin T (hs-cTnT) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) are at high risk

211 nship with N-terminal fragment of prohormone B-type natriuretic peptide (NT-proBNP) are unknown.

212 ombining microRNA panels with N-terminal pro-B-type natriuretic peptide (NT-proBNP) clearly improved

213 ed proportional change in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration fro

214 Increased N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration pre

215 rse; however, the role of amino-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations am

216 sacubitril-valsartan reduces N-terminal pro-b-type natriuretic peptide (NT-proBNP) concentrations.

217 Although N-terminal pro-B-type natriuretic peptide (NT-proBNP) has a strong rela

218 ssess the prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with

219 N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a strong predi

220 assess whether a reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated wit

221 Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) is considered a m

222 on (P < .001); and had higher N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (P < .001)

223 ronolactone and usual care on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels compared w

224 Therapy guided by N-terminal-pro-B-type natriuretic peptide (NT-proBNP) levels may improv

225 ST2 and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were measu

226 -minute walk distance, plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and healt

227 lysis on those with available N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels.

228 lity-of-life (QOL) score, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels.

229 tivity troponin T (hsTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) strongly predict

230 herapy (GDMT) by reducing amino-terminal pro-B-type natriuretic peptide (NT-proBNP) was not superior

231 cardiac troponin T (hs-cTnT) and N-terminal B-type natriuretic peptide (NT-proBNP) were measured usi

232 cardiac troponin I (hs-cTnI), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high-sensiti

233 rs- C-reactive protein (CRP), N-terminal pro b-type natriuretic peptide (NT-proBNP), cardiac troponin

234 ity C-reactive protein (CRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), growth different

235 We studied the association of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitive t

236 edian percent change in serum N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity

237 ost important biomarkers were N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity

238 or age, sex, body mass index, N-terminal pro-B-type natriuretic peptide (NT-proBNP), renal function,

239 ined whether repeated measurements of NT-pro-B-type natriuretic peptide (NT-proBNP), troponin T (Trop

240 ntemporary biomarkers such as N-terminal pro B-type natriuretic peptide (NT-proBNP), urine output (UO

241 igate the association between N-terminal pro-B-type natriuretic peptide (NT-proBNP), which is a marke

242 To determine whether an amino-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided treatment

243 summary score (KCCQ-OSS) and N-terminal pro-B-type natriuretic peptide (NT-proBNP).

244 2 in log-transformed level of N-terminal pro-B-type natriuretic peptide (NT-proBNP).

245 ere blood pressure and plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP).

246 myocardial band (CK-MB), and N-terminal pro-B-type natriuretic peptide (NT-proBNP).

247 diabetic patients selected by N-terminal pro-B-type natriuretic peptide (NT-proBNP).

248 Baseline assessments included N-terminal pro-B-type natriuretic peptide (NT-proBNP).

249 natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP); and 2) body fat

250 ysfunction: C-reactive protein (CRP); NT-pro-B-type natriuretic peptide (NT-proBNP); troponin I; matr

251 s been questioned, and use of N-terminal pro-B-type natriuretic peptides (NT-proBNP) has been preferr

252 ponin T >=6 ng/L] and stress (N-terminal pro-B-type natriuretic peptide [NT-proBNP] >=100 pg/mL) can

253 Early changes in N-terminal pro-B-type natriuretic peptide or high-sensitivity cardiac t

254 ardiac troponin I, NT-proBNP (N-terminal pro-B-type natriuretic peptide), or high-sensitivity C-react

255 porated LA volume, NT-proBNP (N-terminal pro-B-type natriuretic peptide), or left ventricular E/e' (a

256 months, augmentation index at 12 months, BP, B-type natriuretic peptide, or physical function.

257 es showed excellent discriminative power for B-type natriuretic peptide (p = 0.001; 95% CI, 0.99-1.00

258 tein cholesterol (p = 0.005), N-terminal pro-B-type natriuretic peptide (p = 0.004), and left ventric

259 sease (p = 0.003), and higher N-terminal pro-B-type natriuretic peptide (p = 0.02) than those with <=

260 al score (p < 0.0001) or clinical score plus B-type natriuretic peptide (p = 0.02).

261 k stress PLSR (P<0.0001), and N-terminal pro-B-type natriuretic peptide (P<0.0001).

262 walk distance, and NT-proBNP (N-terminal pro-B-type natriuretic peptide; P<0.05 for all).

263 .001), decrease in NT-proBNP (N-terminal pro-B-type natriuretic peptide; P=0.002), and lower levels o

264 nd men, as well as in the total cohort, were B-type natriuretic peptide, peak oxygen consumption by c

265 le risk model assessing 4 clinical variables-B-type natriuretic peptide, pkVO2, NYHA, and angiotensin

266 N-terminal pro-B-type natriuretic peptide, procalcitonin, and waveform

267 sults for soluble ST2 and amino-terminal pro-B-type natriuretic peptide provides early risk assessmen

268 n was greatest in the highest N-terminal pro B-type natriuretic peptide quartile (2.1%).

269 ute kidney injury increased in parallel with B-type natriuretic peptide quartiles (5%, 9%, 15%, and 2

270 ly with hs-TnT (r = 0.44) and N-terminal pro-B-type natriuretic peptide (r = 0.39) but only weakly wi

271 = -0.24; Meng test p = 0.03), N-terminal pro-B-type natriuretic peptide (r = 0.56 vs. r = 0.17; Meng

272 h higher myeloperoxidase (r=0.42, P<0.0001), B-type natriuretic peptide (r=0.25, P=0.001), and asymme

273 , whereas endothelin-1 caused itch-selective B-type natriuretic peptide release.

274 phy, cardiomyocyte death, and N-terminal pro B-type natriuretic peptide release; all are classical ha

275 ge, diabetes, renal function, N-terminal pro-b-type natriuretic peptide serum concentration, and righ

276 nation of soluble ST2 and amino-terminal pro-B-type natriuretic peptide showed excellent discriminati

277 ficantly from "no sepsis" for N-terminal pro-B-type natriuretic peptide, systemic vascular resistance

278 ationships between NT-proBNP (N-terminal Pro-B-type natriuretic peptide), systolic blood pressure, an

279 ing study), high-sensitivity troponin I, and B-type natriuretic peptide ( Table 1 ).

280 culating levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) than HF patients without AF.

281 ure, and change in NT-proBNP [N-terminal pro-B-type natriuretic peptide]), there was a significant in

282 x, (4) circulating NT-proBNP (N-terminal pro-B-type natriuretic peptide), TNF-alpha, IL-6, IL-12, IL-

283 rement of soluble ST2 and amino-terminal pro-B-type natriuretic peptide to clinical parameters for ri

284 ore, left ventricular ejection fraction, pro-B-type natriuretic peptide, troponin I, and C-reactive p

285 F included the combination of N-terminal pro-B-type natriuretic peptide, troponin-T, and urinary albu

286 ces were found between any 2 time points for B-type natriuretic peptide, tumor necrosis factor-alpha,

287 In primary human keratinocytes, B-type natriuretic peptide upregulated genes promoting d

288 alue of blood volume contraction indices and B-type natriuretic peptide variations.

289 roponins were normal, whereas N-terminal pro B-type natriuretic peptide was 10 times the upper limit

290 Elevated N-terminal pro-B-type natriuretic peptide was also associated with an i

291 s; in addition, early rise in N-terminal pro-B-type natriuretic peptide was associated with a better

292 When B-type natriuretic peptide was evaluated, in terms of ca

293 Baseline N-terminal pro B-type natriuretic peptide was measured in 12 301 patien

294 (interquartile range) concentration of BNP (B-type natriuretic peptide) was 124 (69-197) ng/L, NT-pr

295 Mean BNP (B-type natriuretic peptide) was elevated (5743 pg/mL).

296 NT-proBNP (N-terminal pro-B-type natriuretic peptide) was not affected.

297 ular function, end-systolic volume index and B-type natriuretic peptide were most strongly associated

298 odest elevation of NT-proBNP (N-terminal pro-B-type natriuretic peptide) were eligible.

299 V, RVESRI, and log NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) were retained (chi(2), 62.2;

300 % and elevation of NT-proBNP (N-terminal pro-B-type natriuretic peptide), were eligible.